# Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

Study · id `cardio:ct-nct01787396` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01787396](<https://clinicaltrials.gov/study/NCT01787396>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01787396

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 433 participants.

## Technical summary

Registry record NCT01787396. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2015-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 433 participants (enrolled count; ClinicalTrials.gov record NCT01787396, source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)
- Start date: 2013-04 (registry gives no type) (ClinicalTrials.gov record NCT01787396, source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)
- Primary completion: 2015-03 (actual) (ClinicalTrials.gov record NCT01787396, source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT01787396, source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01787396, source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01787396-2015-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Gemigliptin 50mg
- Intervention (Drug): Placebo(Metformin)
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo(Gemigliptin)
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: 54b9c36aef9016bc7f2ff1ba67ea08a82e4d7ac2f2da92529cfc9c4bd9e2a843
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
